Hypoglycemia as a potential risk for patients taking clopidogrel: A systematic review and meta-analysis.

ABSTRACT:

Background

Clopidogrel is a cornerstone antiplatelet drug used in cardiovascular, cerebrovascular, and peripheral artery diseases. The sulfhydryl group of clopidogrel metabolite could induce insulin autoimmune syndrome (IAS) with hypoglycemia as the major symptom. Discontinuing clopidogrel and substituting it with ticagrelor has been revealed as an effective treatment in previous studies. Since hypoglycemia serves as a risk factor for cardiovascular and cerebrovascular events, we aimed to determine the association between hypoglycemia/IAS and clopidogrel and to investigate whether clopidogrel is a modifiable and causal risk factor of hypoglycemia/IAS.

Methods

MEDLINE, Embase, Cochrane databases, and clinical trial registries were searched for randomized controlled trials (RC

SUBMITTER: Chen S 

PROVIDER: S-EPMC10011644 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature